Kidney disease

Product name

Endostatin mouse/rat

Cat-Nr.BI-20742MR
Range0 – 32 nmol/l
Sensitivity0.5 nmol/l (STD2 1 nmol/l)
Incubation time2 h / 30 min
Sample volume5 μl
Sample type

Serum, plasma

Sample preparation

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 3 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Reference values

Mouse sera C57BL6JOlaHsd, 12 weeks (n=11): 6.7 ± 0.8 nmol/l
Wildtype normal mice sera, 12 weeks, male (n=10): 5.4 ± 1.2 nmol/l
Wildtype normal rat sera, 12 weeks, male (n=8): 2.5 ± 0.4 nmol/l

Species

Mouse, rat

Tests96
MethodELISA
Intended use

Intended use:

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs http://www.uniprot.org/uniprot/P39060). The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins. In animal studies, renal Endostatin expression preceded deteriorating kidney function and induced renal fibrosis in aging mice. In humans, Endostatin is expressed during the progression of renal fibrosis in tubular cells of injured tissue .In renal micro-vascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation.
Thus endostatin may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial- and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome. In a cohort of critically ill patients, plasma endostatin improved AKI prediction based on clinical risk factors. Endostatin has evolved as a molecular target and is currently under investigation in clinical trials.

Intended applications:

  • Micro-vascular injury
  • Chronic kidney disease
  • Atherosclerosis
  • Ischemia
  • Sepsis
  • Preeclampsia
Product informations

Back to overview